Affimed (NASDAQ: AFMD)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Affimed Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Affimed Company Info
Affimed Therapeutics B.V.
News & Analysis
The clinical-stage biotech focuses on immuno-oncology therapies.
An analyst's downgrade brings out the bears for the European cancer treatment developer.
This billionaire-guided hedge fund went bargain-shopping in the second quarter.
The biotech's experimental blood cancer treatment could be a major advancement.
Finding stocks with significant upside before the rest of the market sees what's happening can be highly profitable.
Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now.
The biotech's early-stage trial results are turning heads on Wall Street today.
Positive trial results regarding the company's pipeline are buoying the stock's price.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/23/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
AFMD earnings call for the period ending September 30, 2021.
AFMD earnings call for the period ending June 30, 2021.
AFMD earnings call for the period ending September 30, 2020.
AFMD earnings call for the period ending June 30, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.